Grade My Investments
HomeFree Stock Grades › NERV

Minerva Neurosciences, Inc. (NERV) Stock Grade

NERV · Healthcare

B
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$34.0M
P/E Ratio
Revenue Growth (YoY)
0.0%
Net Margin
0.0%
Return on Equity
208.5%
Dividend Yield
None

About Minerva Neurosciences, Inc.'s fundamentals

Minerva Neurosciences is a small-cap biotechnology company with a market capitalization of $34.0 million that reported no year-over-year revenue growth and posted a net loss in its latest annual statement, resulting in a 0.0% net margin. The company does not currently pay a dividend. The company's return on equity metric of 208.5% reflects significant equity volatility typical of unprofitable biotech firms with minimal equity bases rather than operational strength.

Track NERV free — no credit card required. Live grade + monthly AI report →